Zoekresultaten - You searched for Patients

335 results

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Read more

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Read more

Galapagos - Positive topline results with GLPG1972 in osteoarthritis patients

Read more

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

TiGenix strengthens European IP protection around lead development program Cx601

Read more

Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany

Read more

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests

Read more

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

Read more

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla(TM) platform

Read more

Acacia Pharma announces its intention to launch an initial global offering and to list its shares on Euronext Brussels

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

Biocartis Selected for Oral Presentation at Cancer Research Meeting

Read more

eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Read more

Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates

Read more

Galapagos announces ISABELA Phase 3 program in IPF

Read more

MDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System

Read more

Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Read more

Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF

Read more

TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Read more

Tau prevents synaptic transmission at early stage of neurodegeneration

Read more

Biocartis Group NV: Biocartis launches CE-marked IVD NRAS test for colorectal cancer

Read more

TiGenix Launches Global Phase III Trial for Cx601

Read more

TiGenix opens US headquarters in Cambridge, MA

Read more

eTheRNA immunotherapies advances In-Vivo mRNA Cancer Immunotherapy into first Oncology Clinical Studies

Read more

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

Read more

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Read more

Celyad announces initiation of the SHRINK trial

Read more

Dosing of First Patient with investigational agent OMO-1

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Read more

Galapagos - Update on progress in cystic fibrosis programs

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

Read more

MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

Read more

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Read more

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

Read more

ThromboGenics Business Update - Q1 2018

Read more

Metastatic breast cancers: Characterising the profile of metastases for improved treatment

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

Kiadis Pharma raises €5 million in private placement with institutional investors

Read more

Mindbytes expands to North America to develop next generation serious medical games driven by artificial intelligence

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

Read more

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Read more

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Read more

Scientists pinpoint surprising origin of melanoma

Read more

ThromboGenics Business Update - Q3 2017

Read more

GAMIAN-Europe & CMAST announce collaborative partnership

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

Read more

Ionis Pharmaceuticals licenses novel antisense drug for the treatment of centronuclear myopathy to dynacure

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

Mindbytes initiates oncology R&D program focused on patient empowerment and is selected as one of five finalists for Astellas Oncology C3 Prize®

Read more

Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting

Read more

Scientists shed light on a tumor-suppressive protein In metastases

Read more

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

reMYND enters into license agreement with Novo Nordisk

Read more

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Read more

Patient centricity in Clinical Research

Read more

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

Read more

HDAC6 inhibitors protect against neuronal damage and have therapeutic potential in both neurology and oncology

Read more

Convert Pharmaceuticals secures EUR 13,6 million to develop anti-cancer drugs

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

Read more

Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model

Read more

Biocartis Q1 2018 business update

Read more

Biocartis: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

Gilead and Galapagos announce results with filgotinib in the phase 2 equator study in psoriatic arthritis and progression into phase 3 for the selection study in ulcerative colitis

Read more

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Read more

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Read more

Biocartis Group NV: Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Read more

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Read more

Biocartis present at investor event VFB Happening this Saturday 25 March, Antwerp, BE

Read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

Read more

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Read more

Kiadis Pharma announces Annual Results for the year ended December 31, 2016

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Read more

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Read more

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

Galapagos reports first quarter 2017 results

Read more

Celyad initiates second dose escalation in THINK trial in first US patient

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Read more

VIB: Shortage of progranulin is a frequent cause of frontotemporal dementia

Read more

TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York

Read more

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

Read more

Galapagos NV: Seven abstracts on filgotinib accepted by EULAR 2017

Read more

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Read more

Biocartis Group NV: Study demonstrating high performance of Idylla(TM) liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Read more

Celyad Announces First Quarter 2017 Business Update

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

Celyad obtains additional US patent for cancer treatment

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

Biocartis wins prestigious Galenus Prize with its Idylla(TM) NRAS-BRAF Mutation Test for colorectal cancer

Read more

Scientists give tumor-fighting cells a boost in battling bone marrow cancer

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis

Read more

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

Read more

SelectMDx to be Distributed Across Middle East by IPS Genomix

Read more

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Read more

QBD Webinar on validation of mobile apps

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

Read more

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

Read more

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

Read more

Celyad Reports First Half 2017 Financial Results and Operational Progress

Read more

TiGenix obtains commercial production license for expanded manufacturing facility

Read more

Biocartis announces H1 2017 results

Read more

ThromboGenics Business Update - H1 2017

Read more

TiGenix strengthens US operations with senior appointments

Read more

Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

Read more

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Read more

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Read more

2nd Symposium : « Introduction of the Next-Generation-sequencing technology in routine analysis in the Belgian healthcare »

Read more

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship

Read more

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Read more

ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

ONTOFORCE wins the EIT Venture Award 2017

Read more

argenx reports third quarter 2017 financial results and provides business update

Read more

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

Read more

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

Read more

MDxHealth Nine Month Trading Update

Read more

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017

Read more

Bone Therapeutics Business Update for Third Quarter 2017

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

Count your blessings: Quantitative Microbiome Profiling

Read more

Celyad Announces Third Quarter 2017 Business Update

Read more

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Read more

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Read more

Mithra Announces 36-month Shelf Life Extension for Tibelia®

Read more

Fast Track Diagnostics and UgenTec announce new interpretation software for all FTD real-time PCR multiplex kits

Read more

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

Read more

Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

Read more

Bone Therapeutics Launches Equity Placement

Read more

Confo Therapeutics enters into drug discovery collaboration with Roche

Read more

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Read more

Takeda announces its intention to acquire TiGenix

Read more

Ablynx strongly believes unsolicited conditional proposal from Novo Nordisk fundamentally undervalues the company and its future prospects

Read more

Imec’s SWEET study Collects World’s Largest Dataset on Stress Detection

Read more

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

Read more

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease

Read more

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

Read more

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Read more

Bone Therapeutics provides business outlook and announces its financial calendar for 2018

Read more

UgenTec and MDxHealth sign partnership agreement for software to support interpretation of molecular test results

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

Ablynx announces 2017 full year results

Read more

MDxHealth financial results

Read more

Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease

Read more

Key Considerations in Health Care Product Development

Read more

MDxHealth contract SelectMDx with Roman Hospital

Read more

argenx reports fourth quarter business update and full year 2017 financial results

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

Read more

VIB Plant-derived volatiles may serve as future antifungals

Read more

So hot it hurts - Leuven researchers uncover ion channel trio that mediates painful heat sensing

Read more

European scientists unite to track all cells in the human body

Read more

Novosanis’ medical device Colli-Pee® prefilled with urine preservative now CE-certified

Read more

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

Read more

argenx appoints Keith Woods as Chief Operating Officer

Read more

MDxHealth Provides First Quarter 2018 Business Update

Read more

Bone Therapeutics Reports Full Year 2017 Results

Read more

ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

Read more

Bone Therapeutics Business Update for First Quarter 2018

Read more

Israeli endoscopy startup 3NT Medical announces initial closing of $15M to include key strategic investor

Read more

Do you have to become officially a BIOBANK under the new Belgian law?

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

Sanofi and Ablynx announce the successful results of the initial tender offer period for ablynx and commencement of squeeze-out tender period

Read more

MDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting

Read more

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149

Read more

VIB: New genes found only in humans shed light on unique features of brain development

Read more

MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

Read more

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

Read more

Imec demonstrates compact low-power 140GHz CMOS radar with on-chip antennas

Read more

argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018

Read more

TiGenix announces a change in its Board of Directors and its Management Team

Read more

The first veterinary stem cell product recommended for approval in Europe becomes a reality

Read more

MDxHealth's SelectMDx Test Successfully Stratifies Men

Read more

Galapagos: Topline results of PELICAN trial and update on triple combo development plans

Read more

Novosanis signs an agreement to provide MDxHealth a customized urine collection device

Read more

Galapagos: Publication of the annual report

Read more

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence

Read more

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

Read more

Novosanis receives Interreg CrossCare grant for its Colli-Pee™ device

Read more

TiGenix reports 2016 full year results

Read more

Galapagos increases share capital through warrant exercises

Read more

New Study Shows MDxHealth's SelectMDx Test is Cost-Effective for Biopsy Selection

Read more

Symposium on Sepsis

Read more

Specialized blood vessels enhance tumor-fighting immunotherapy

Read more

Galapagos raises $338 million gross proceeds in a U.S. public offering

Read more

Galapagos announces launch of proposed public offering

Read more

REVERSED BREXIT: £250 MILLION FOR BART DE STROOPER'S DEMENTIA RESEARCH

Read more

Biogazelle offers unique mRNA sequencing on plasma

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Read more

Galapagos announces capital increase

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx

Read more

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Read more

argenx reports first quarter 2017 financial results and provides business update

Read more

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Read more

VIB: A new unexpected key player in melanoma development identified

Read more

MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

MDxHealth Trading Update: January to April 2017

Read more

Biocartis Group NV: Biocartis announces its new CEO

Read more

Bone Therapeutics Business Update for First Quarter 2017

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

VIB: Researchers identify nutrient metabolism that drives breast tumor metastasis

Read more

ThromboGenics Business Update - Q1 2017

Read more

ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men

Read more

SelectMDx for Prostate Cancer Guides Patient Selection for mpMRI

Read more

Biocartis Group NV: Results of the annual shareholders' meeting held on 12 May 2017

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

Galapagos to hold Annual R&D Update 2017 on 20 June

Read more

Galapagos creates new warrant plan

Read more

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

Read more

Researchers discover mechanism behind rapid smell source localization

Read more

Innovative software Moon autonomously diagnoses rare diseases within minutes

Read more

Cochlear acquires exclusive licence to Artificial Intelligence assistant

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

ThromboGenics to Present the Industry Pipeline of DME Treatments

Read more

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

Read more

TiGenix announces final equity payment for cardiac platform acquisition

Read more

Services

Read more

Biocartis launches CE-marked IVD test for lung cancer

Read more

Daily Newsflash- 14/06/17

Read more

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

Read more

Daily Newsflash- 15/06/2017

Read more

MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test

Read more

Galapagos' R&D Update 2017: rapidly advancing our product candidates

Read more

Daily Newsflash- 27/06/17

Read more

MDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Daily Newsflash- 29/06/17

Read more

iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development

Read more

Lack of Knowledge on Clinical Advances Achieved by New Generation of Biomarker Tests for Prostate Cancer

Read more

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Read more

Ablynx & Sanofi enter into a strategic collaboration to develop nanobody product candidates

Read more

Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer’s disease

Read more

ConfirmMDx Featured in OncologyLive Magazine

Read more

Celyad announces new agreements with Celdara medical and Dartmouth College

Read more

Interreg 2 Seas Project DERMA Industrial Matchmaking and Showcase Event

Read more

iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Read more

ConfirmMDx Study Provides Further Validation of Epigenetic Risk Profile

Read more

Navigation and spatial memory: new brain region identified to be involved

Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Read more

argenx reports second quarter business update and half-year 2017 financial results

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

Press Release - Life Sciences & Biotechnology

Read more

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

Read more

Bone Therapeutics announces H1 results for 2017

Read more

MDxHealth Announces First Half 2017 Financial Results

Read more

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

Read more

Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017

Read more

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

Read more

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

Read more

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Read more

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI

Read more

Biocartis Group NV: Results of the extraordinary shareholders' meeting held on 11 September 2017

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

pi life sciences consultancy launches Music For Life-campaign to lift the taboo on young dementia

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

Trainings - CONNECT / EDUCATE

Read more

Promethera Biosciences to Present at Several International Partnering and Scientific Conferences this Fall

Read more

TiGenix to participate and present at key investor and business development meetings

Read more

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Read more

Key Considerations in Health Care Product Development

Read more

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Ablynx establishes subsidiary in the USA and appoints a general manager

Read more

Newly described process in Parkinson’s protein as a potential new therapy route

Read more

MyCartis appoints Philippe Stas as CEO

Read more

Press Release - Life Sciences & Biotechnology

Read more

iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting

Read more

ThromboGenics Strengthens Leadership Team

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference

Read more

Promethera Biosciences Provides Update on Executive Management Team

Read more

Biocartis successfully raises EUR 80 million in an equity placement

Read more

Follow-up info flanders.bio-CMAST Partner Day

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Ablynx to host webcast about Phase III Hercules Study

Read more

Press Release - Life Sciences & Biotechnology

Read more

Press Release - Life Sciences & Biotechnology - 14/12/2017

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

Read more

Biocartis - Disclosure of a transparency notification

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Read more

Disclosure of a transparency notification

Read more

European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects

Read more

Biocartis Establishes R&D Center in the US

Read more

Thank you for attending the latest flanders.bio-Janssen Partner Day

Read more

Press Release - Life Sciences & Biotechnology - 30/03/2018

Read more

Biocartis Group NV: Biocartis announces publication of its 2017 annual report

Read more

Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Promethera Biosciences Announces Updates to its Board of Directors

Read more

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma

Read more

Biocartis: Results of the annual shareholders' meeting held on 11 May 2018

Read more

Promethera Biosciences Establishes Branch Office in Tokyo

Read more

Press Release - Life Sciences & Biotechnology - 15/05/2018

Read more

ProDigest: PROMISE

Read more

Press Release - Life Sciences & Biotechnology - 23/05/2018

Read more

Thank you for attending the latest flanders.bio - Roche Diagnostics Partner Day

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

TiGenix: Transparency Information

Read more

Biocartis launches innovative Idylla(TM) MSI Assay

Read more